Improved IR of rosiglitazone-treated T2D subjects was associated with increased S1P, suggesting the possibility that S1P signalling maybe mechanistically linked with improved IR and adipogenesis. The gene discussed is MBTPS1; the disease is type 2 diabetes mellitus.